此次整合标志着多组学研究新时代的开启，生物医学研究有望迎来新的发展机遇。 摘要 ： 基因测序巨头斥资3.5亿美元将蛋白质组学技术领导者纳入麾下，旨在为客户提供更全面的多 组学解决方案。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 美国加利福尼亚州圣迭戈——2026年1月30日，因美纳公司宣布已完成对蛋白质组学技术领 域领先企业SomaLogic的收购。此次交易总价值达3.5亿美元，另加高达7500万美元的绩效 里程碑款项。 这 一 收 购 标 志 着 因 美 纳 在 实 施 2024 年 提 出 的 多 组 学 战 略 过 程 中 取 得 重 要 进 展 。 通 过 整 合 SomaLogic高度差异化的蛋白质组学技术，因美纳将增强在基因组学与蛋白质组学领域提供 可扩展洞察的能力。 因美纳首席执行官Jacob Thay sen表示："欢迎SomaLogic团队加入因美纳，这是我们落实 2024年制定的多组学战略 的重要里程碑。" 此前，在2025年6月宣布收购协议时，因美纳曾表示预计该业务将在2027年实现非GAAP的 经营收入盈利。 ...

Core Insights - The π-HuB Park industrial park has been established in Guangzhou as a key component of the international scientific initiative π-HuB, marking a new phase of industrial collaboration and ecological development in the field of proteomics [1][4][9] - The π-HuB initiative aims to create a comprehensive "real-time panorama" of the proteome, facilitating advancements in biomedicine, clinical diagnostics, and agricultural biotechnology [2][3] - The establishment of the industrial park is expected to enhance Guangzhou's competitiveness in the global biomedicine sector and help capture opportunities in the trillion-dollar precision medicine market [9][10] Industry Overview - The global proteomics market is projected to grow at a compound annual growth rate (CAGR) of 12.4% from 2024 to 2029, indicating significant investment and interest from major international players [3] - The π-HuB initiative has garnered support from over 114 top scientific teams across more than 20 countries and regions, highlighting its international collaboration and significance [2] Strategic Collaborations - The industrial park has formed strategic partnerships with leading companies such as Danaher, Thermo Fisher Scientific, and Dary Biotech, which will facilitate the development and commercialization of innovative technologies and products [1][9] - π-HuB will collaborate with Danaher to establish a joint innovation center aimed at nurturing and investing in high-potential early-stage projects [8] Regional Advantages - Guangzhou's strong medical and industrial foundation, including over 7,000 healthcare institutions and nearly 7,000 biopharmaceutical companies, positions it as a key player in the proteomics field [6] - The local government is providing comprehensive support in terms of platform development, talent acquisition, clinical resources, and financial backing to facilitate the growth of the π-HuB initiative [6] Future Prospects - The establishment of the π-HuB Park is expected to attract more scientists and entrepreneurs to Guangzhou, fostering the growth of leading companies in the proteomics industry and transforming technological advantages into industrial strengths [10]